Navigation Links
CONRAD receives $28.5M Gates Foundation grant for HIV prevention research
Date:11/30/2007

Arlington, VA (November 30, 2007) The CONRAD Program of the Eastern Virginia Medical School today announced that it has received a $28.5 million grant from the Bill & Melinda Gates Foundation to develop microbicides for HIV prevention. To date, the Gates Foundation has awarded a total of $65 million to CONRAD for microbicide research.

The award will support the development of new combination microbicides, research on novel and improved in vitro and small-animal models to test microbicide safety and efficacy, validation of clinical biomarkers and testing of the new microbicide candidates for clinical safety.

Despite setbacks in the HIV prevention field over the past year, the global effort to develop effective new prevention tools, including microbicides, must go on, said Henry Gabelnick, Executive Director of CONRAD. We are grateful for the continued support of the Gates Foundation, and we are inspired by its commitment to making real progress in global health.

Microbicides are topical substances used intravaginally to potentially prevent HIV infection. Effective microbicides could be an important HIV prevention option for women, who account for approximately half of all people living with HIV globally.

CONRAD has served as a resource for the microbicide field for the past twenty years, and in that capacity, has provided support for preclinical, early clinical research and Phase III clinical trials for several microbicide candidates, many of which were funded by the Gates Foundation and/or USAID. New microbicide candidates CONRAD is currently researching contain several ingredients with different types of activity against HIV. Dr. Gabelnick continued, Due to the multiple pathways involved in mucosal infection and the number of new infections attributable to viruses that contain drug resistance-associated mutations, development of a combination microbicide is likely to be important to achieve successful prevention of sexual transmission of HIV.

The microbicide field has accumulated a wealth of experience and understanding that is critical for accelerating progress toward an effective microbicide, said Dr. Gustavo Doncel, Director of Preclinical Research at CONRAD. The contributions of the Gates Foundation have created a synergy within the microbicide field that we hope will result in the development of a tool that will be a major advance in the fight against HIV.

Even if the first microbicide that is approved is not 100% effective, modeling studies suggest that it could still have a major impact on public health, provided it is used in combination with other HIV prevention methods.


'/>"/>

Contact: Annette Larkin
annettelarkin@rationalpr.com
703-772-6427
CONRAD
Source:Eurekalert

Related biology news :

1. Rutgers Genetics receives $7.8 million for autism research
2. Herr receives Heinz Award for Technology, the Economy and Employment
3. UCI receives $5M from Edwards Lifesciences
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
6. UC Riverside biologist receives prestigious MacArthur Fellowship
7. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
8. Penn biochemist receives NIH New Innovators Award
9. NYUs Center for Genomics & Systems Biology receives $4.4 million NSF grant
10. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
11. Alaska graduate program in sustainability receives $3.2 million award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... and utilizing the experience of both in-house personnel and consultants, VetStem constructed and ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
(Date:2/21/2017)... 21, 2017   Logicalis Healthcare Solutions , the ... and managed services provider ( www.us.logicalis.com ), today announced ... Epic. The new service will help hospital CIOs make ... giving physicians, nurses and other clinicians immediate access to ... This will allow hospital IT staff to focus on ...
(Date:2/21/2017)... , Feb. 21, 2017   Invitae Corporation ... information companies, today announced that members of the company,s ... 37th Annual Health Care Conference on Monday, March 6, ... Pacific in Boston, Massachusetts . ... may be accessed by visiting the investors section of ...
Breaking Biology Technology: